UCB S.A.: Crohn Disease trials

The registry lists 29 Crohn Disease studies with UCB S.A. as lead sponsor. 0 are open to participants now and 20 have results posted.

Phase 1 3Phase 2 6Phase 3 16No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)CompletedNCT04163016Phase 1Results posted
• Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's DiseaseCompletedNCT03357471Phase 3Results posted
• A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating MothersCompletedNCT02154425Phase 1Results posted
• A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the PlacentaCompletedNCT02019602Phase 1Results posted
• Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab PegolCompletedNCT01190410Phase 2Results posted
• The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and AdolescentsTerminatedNCT00899678Phase 2Results posted
• SECURE, the Cimzia ® Crohn's Disease Post-Marketing RegistryCompletedNCT00844285Results posted
• A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's DiseaseCompletedNCT00552344Phase 3Results posted
• Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's DiseaseCompletedNCT00552058Phase 3Results posted
• Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's DiseaseCompletedNCT00356408Phase 3Results posted
• Corticosteroid Sparing Effect of Certolizumab in Crohn's DiseaseTerminatedNCT00349752Phase 3Results posted
• Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's DiseaseCompletedNCT00333788Phase 3Results posted
• Maintenance Study of Certolizumab Pegol (CZP) in Crohn's DiseaseCompletedNCT00329550Phase 2Results posted
• Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)CompletedNCT00329420Phase 2Results posted
• Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to InfliximabCompletedNCT00308581Phase 3Results posted
• Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed InfliximabTerminatedNCT00307931Phase 3Results posted
• Mucosal Healing Study in Crohn's Disease (CD)CompletedNCT00297648Phase 3Results posted
• Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's DiseaseCompletedNCT00291668Phase 2Results posted
• A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's DiseaseCompletedNCT00160706Phase 3Results posted
• A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]CompletedNCT00160524Phase 3Results posted
• A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's DiseaseWithdrawnNCT04643483Phase 3
• CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)No longer availableNCT03559660
• UCB Cimzia Pregnancy Follow-up StudyTerminatedNCT02775656
• A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's DiseaseWithdrawnNCT01635621Phase 2
• Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)TerminatedNCT01577264
• A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's DiseaseWithdrawnNCT00358683Phase 3
• Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining FistulasWithdrawnNCT00354367Phase 3
• A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)CompletedNCT00152490Phase 3
• Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).CompletedNCT00152425Phase 3